Skip to main content
. 2023 Sep 19;17(1):1–21. doi: 10.1080/19336918.2023.2258539

Figure 4.

Figure 4.

Combination of immunotherapies in HCC.

Multiple tyrosine kinase inhibitors, VEGF inhibitors, CTLA4 inhibitors, PD1 and PDL1 inhibitors are being tested in combination therapy. It demonstrates some promising results in the treatment of hepatocellular carcinoma.